CLINICAL_TRIALS
trial_result
· 2022-04-26
Clinical Trial Update: Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) [Phase 3]
Summary
Phase 3 TASUKI-52 trial evaluating ONO-4538 (nivolumab) in non-squamous non-small cell lung cancer has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-04-26